Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that the U.
Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today key leadership appointments to strengthen the company’s clinical and commercial capabilities.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported its third quarter 2016 financial results and provided an update on recent events and development timelines for its therapeutic …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced today that the U.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander ‘Sandy’ Macrae, M.
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, presented new preclinical data from the Company’s proprietary In Vivo Protein Replacement Platform™ …
The biotech sector has had a really cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 26% so far in …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.